<p>US drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.</p><p>Pfizer said its decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use.</p><p>The company said it does not anticipate that the withdrawal will impact its full-year 2024 financial guidance.</p>
<p>US drugmaker Pfizer said on Wednesday it would voluntarily withdraw its therapy Oxbryta, used for the treatment of sickle cell disease, in all markets where it is approved.</p><p>Pfizer said its decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use.</p><p>The company said it does not anticipate that the withdrawal will impact its full-year 2024 financial guidance.</p>